Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, specialty drugmaker Impax Laboratories (Nasdaq: IPXL) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Impax's business and see what CAPS investors are saying about the stock right now.

Impax facts

Headquarters (Founded)

Hayward, Calif. (1993)

Market Cap

$1.55 billion



Trailing-12-Month Revenue

$879.51 million


CEO Larry Hsu (since 2006)

CFO Arthur Koch, Jr. (since 2005)

Return on Equity (Average, Past 3 Years)



$348.4 million / $0


Mylan (Nasdaq: MYL)

Teva Pharmaceutical (Nasdaq: TEVA)

Watson Pharmaceuticals (NYSE: WPI)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 94% of the 207 members who have rated Impax believe the stock will outperform the S&P 500 going forward. These bulls include kleyau and MoabRocks.

Just last month, kleyau highlighted Impax as a healthy bargain: "Spectacular growth, effective management, huge market. Bumpy earnings keep the price down."

In fact, Impax currently sports a particularly paltry P/E of 6.3. That represents a clear discount to listed competitors Mylan (32.4), Teva (13.1), and Watson (37.2).

CAPS member MoabRocks elaborates on the bull case:

This is an interesting niche in the generic pharmaceutical market. The creation of sustained-release products is vital in many areas to create a valuable generic alternative to innovator products. This technology should create lasting partnerships for [Impax] and the potential for growth. As more products requiring sustain-release formulations lose patent protection if positioned properly this company could continue to be very interesting.

What do you think about Impax, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Teva. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.